Tricia Parker, Joy Vongspanich Dray and Teresa Kwong

Tricia Parker, Pharm.D., BCPS

Current Title(s):

  • Assistant Chief, UC Davis Medical Center Inpatient Pharmacy Services
  • Health Sciences Associate Clinical Professor,
    UC San Francisco School of Pharmacy
  • Health Sciences Assistant Clinical Professor,
    UC Davis School of Medicine,
    Division of Pulmonary & Critical Care Medicine

At UC Davis Medical Center since: 1999

Program Director since: 2009

Education:

  • Pharm.D., Creighton University School of Pharmacy and Health Professions, 1999
  • Pharmacy Practice Residency, UC Davis Medical Center, 2000

Professional Biography

Dr. Patricia (Tricia) Parker is the Assistant Chief of Inpatient Pharmacy Services at UC Davis Medical Center. Dr. Parker joined the UC Davis Medical Center team in 1999 as one of three Acute Care PGY1 residents, and accepted a career position upon graduation as a Critical Care Staff Pharmacist. In 2003, she was promoted to a Clinical Services Supervisor where she practiced in a split clinical (Critical Care & Nutrition Support) and administrative role for the next five years. Serving as Assistant Chief/Clinical Coordinator since 2008, Dr. Parker is currently responsible for the oversight of planning, implementing and management of clinical pharmacy practice throughout the inpatient setting, assuring efficient and effective clinical services.

Dr. Parker's commitment to hospital pharmacy practice began in 1988 where she worked as a hospital technician for seven years before entering pharmacy school at Creighton University in Omaha, Nebraska in 1995.

In addition to her Assistant Chief/Clinical Coordinator role, she has since obtained faculty positions at both UC San Francisco School of Pharmacy and UC Davis School of Medicine as a Health Sciences Associate and Assistant Professor, respectively. In 2009, Dr. Parker was appointed as the PGY-1 Acute Care Residency Director for UC Davis Medical Center.

Selected Publications

Delich PC, Siepler JK, Parker, P. Liver Diseases. In: The ASPEN Nutrition Support Core Curriculum. Gottschich MM, Editor. American Society for Parenteral and Enteral Nutrition. Silver Spring, MD pp. 540-557.

Stebbins MR, Cutler TW, and Parker PL. Assessment of Therapy and Medication Therapy Management. In Applied Therapeutics: The Clinical Use of Drugs. 9th edition. Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ, Alldredge BK, Corelli RL, Williams BR eds. Lippincott, Williams & Wilkins: Baltimore, MD, 2008.

Clemens E, Cutler T, Canaria J, Pandya K, and Parker P. Prescriber Compliance with a New Computerized Insulin Guideline for Noncritically Ill Adults. The Annals of Pharmacotherapy 2011; February, Volume 45.

Stebbins MR, Cutler TW, and Parker PL. Assessment of Therapy and Medication Therapy Management. In Applied Therapeutics: The Clinical Use of Drugs. 10th edition. Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ, Alldredge BK, Corelli RL, Williams BR eds. Lippincott, Williams & Wilkins: Baltimore, MD, 2012.

Cutler TW, Parker PL. Medication Errors in the Intensive Care Unit. ICU Management, vol. 9, no. 2, pp. 12-15.

Teresa Kwong, Pharm.D., BCPS, BCACP

Current Title(s):

  • Senior Pharmacist, UC Davis Health Clinics
  • PGY1 Pharmacy Residency Director – Ambulatory Care
  • Assistant Professor, UC San Francisco School of Pharmacy
  • Assistant Processor, University of the Pacific School of Pharmacy

At UC Davis Health since: 2005

Program Director since: 2008

Education:

  • Pharm.D., University of the Pacific, 2005
  • PGY-1 Pharmacy Practice Residency, UC Davis Medical Center, 2005 - 2006

Professional Biography

Dr. Teresa Kwong is an ambulatory care pharmacist at UC Davis Health Clinics. She is board certified in ambulatory care and pharmacotherapy. Dr. Kwong began her pharmacy career at UC Davis Health in 2005. She completed a PGY1 pharmacy practice residency in 2006. Upon completion of her residency she accepted a position with the UC Davis Health ambulatory care clinics. She has held roles in the anticoagulation, refill, medication therapy management, hypertension/hyperlipidemia, and controlled substance clinics. She has been a PGY-1 pharmacy residency program director since 2008.  

Selected Publications

Batth, S, Branch, J, Giannini, J, Kwong, T, and Wilson, M. Impact of a Clinical Pharmacist’s Interventions on Patient’s Knowledge of Direct Oral Anticoagulants (DOAC). Presented at the Anticoagulation Forum National Conference 2017.

Nguyen, J, Dang, J, and Kwong, T. Evaluation of Safety and Effectiveness of 12 Week Monitoring of Patients Stable on Warfarin at UC Davis Anticoagulation Clinic. Presented at the American College of Clinical Pharmacy Annual Meeting 2013.

Mendoza, P, Kwong, T, Duong, L, and Burton, J. Evaluation of Causes of Supratherapeutic INR at the UC Davis Health Anticoagulation Clinic. Presented at the American Society of Health System Pharmacists Midyear 2013.

Kwong, T, Shepard, T, Burton, J, Bandy, J, Branch, J, and Giannini, J. Evaluating Time in Therapeutic Range of Warfarin Patients Self Testing With Point of Care Devices. Presented at California Society of Health-System Pharmacists Seminar 2011.

Louie, D, and Kwong, T. Identifying Methods to Improve the Referral Process in Patients Discharged from a University Hospital to an Outpatient Anticoagulation Clinic. Presented at University Health System Consortium meeting at the American Society of Health-System Pharmacists Midyear 2010.

Kwong, T, Sexton, L, Burton, J, Bandy, J, Branch, J, and Giannini, J. Development and Production of a Patient-Specific Warfarin Education Video for a University Teaching Hospital and Outpatient Anticoagulation Clinic. Presented at American Society of Health-System Pharmacists Midyear 2009.

Nguyen, K, Kwong, T, Giannini, J, and Mowers, R. Retrospective Analysis of TZD Utilization Based on FDA Safety Warnings. Presented at University Health System Consortium meeting at the American Society of Health-System Pharmacists Midyear 2008.

Kwong T. (2006). New Treatment Options for Deep Vein Thrombosis and Pulmonary Embolism. UC Davis Medical Center Drug Perspectives. 1, 3-4.

Kwong, T, Dager, W, and King, J. Evaluation of the Use of Low Molecular Weight Heparins for Venous Thromboembolism Prophylaxis in Trauma Patients. Presented at University Health System Consortium meeting at the American Society of Health-System Pharmacists Midyear 2005.

Joy Vongspanich Dray, Pharm.D., BCACP, AAHIVP

Current Title(s):

  • Senior Clinical Pharmacist, Solid Organ Transplant
  • PGY1 Residency Program Director
  • Assistant Clinical Professor, UCSF School of Pharmacy

At UC Davis Medical Center since: 2010

Program Director since: 2017

Education:

  • Pharm.D., University of California, San Francisco 2010·        
  • PGY1 Ambulatory Care/HIV Residency, UC Davis Medical Center, 2011

Professional Biography

Dr. Joy Vongspanich Dray is a Senior Ambulatory Care Clinical Pharmacist at UC Davis Health. She completed her PGY1 Ambulatory Care/HIV residency here at UC Davis in 2011 and went on to work as a clinical pharmacist practicing in solid organ transplant. There she helped to develop the clinical services of the solid organ transplant specialty pharmacy. In 2013 she returned to her first passion, serving the HIV population at the Center for AIDS Research and Education Services (CARES). Since then, Dr Dray has continued to practice in both areas of clinical specialties expanding the role of clinical pharmacists in both specialty clinics. Dr Dray has a special interest in volunteering abroad, having served in India, Thailand, Kenya and Uganda. She hopes to continue to pursue her love of international service and spread awareness to future residents by co-precepting an elective rotation in rural Uganda.

Dr Dray is board certified in Ambulatory Care and credentialed by the American Academy of HIV medicine as a practicing HIV Pharmacist. In addition, she holds a volunteer faculty position with the UCSF School of Pharmacy and has earned various pharmacy awards, most notably Preceptor of the Year, 2016-2017.

Selected Publications

Yu M, Dray J, Nguyen J. Analysis of Clinical Outcomes Associated with Generic to Generic Interchange of Tacrolimus in Renal Transplantation. Presented at ACCP 2019.

Asmuth DM, Chen AY, Utay NS, Torok N, Poole PL, Vongspanich J, Haight KR, Sumasunderam AD, Byambaa E, Li X-D, Cohen ST, Berglund L, Holodniy M, Michalak TI. Impact of Occult HCV Infection (OCI) on Systemic Immune Activation after DAA Therapy. In Abstracts for the 25rd Conference on Retroviruses and Opportunistic Infections. Boston MA, USA, March 4-7, 2018. Abstract 636.

Mitchell Y, Volpendesta J, Wilson M, Dray J. Evaluation of efficiency and patient perception of transplant medication education after pharmacist created education video. Presented at Healthcare Con and American Transplant Congress 2018.

Hluhanich R, Vongspanich J, Poole P, Wilson M. Management of Hypertensive HIV-positive Patients in a Patient-Centered Medical Home. Presented at IDSA and ACCP 2014.

Created “Transplant medication education” videos. Available on UCD Health CCTV and websites

William Dager, Pharm.D., BCPS, (AQ-Cardiology)

Current Title(s):

  • Pharmacist Specialist, UC Davis Medical Center
  • Clinical Professor of Medicine, UC Davis School of Medicine
  • Clinical Professor of Pharmacy, Touro University College of Pharmacy

At UC Davis Medical Center since: 1985

Program Director since: 2009

Education:

  • Pharm.D., UC San Francisco School of Pharmacy, 1985
  • General Pharmacy Residency, UC Davis Medical Center, 1986
  • Nephrology Pharmaceutical Care Preceptorship, University of Pittsburgh, 1995

Professional Biography

Bill is a board-certified pharmacotherapy specialist with added qualifications in cardiology. He is a clinical specialist at UC Davis Medical Center, where his practice focus is cardiology, cardiovascular surgery and anticoagulation.  He is also involved in pharmacokinetics and management of selected critical care-related situations and mentors residents in nephrology and non-malignant hematology.  He is the director of the PGY-2 residency in cardiology. He currently holds three adjunct academic recognitions as a full professor, and one of 6 pharmacists recognized as a Master in Critical Care Medicine (MCCM).

Bill is a recipient of multiple teaching and mentoring awards, including the ACCP Best Practice award in 2008, the Long teaching award from UCSF and the outstanding mentor award from the ACCP Cardiology PRN. He is a reviewer and/or editorial board member for multiple medical journals, including chair of the Editorial Advisory Board panel on anticoagulation for the Annals of Pharmacotherapy. He is the co-chair for the Society of Critical Care Medicine 2019 Congress and currently serves as a Reagent for the American College of Critical Care Medicine.

Bill has authored approximately 100 peer reviewed articles, over 30 book chapters, and is a co-editor of the ASHP Anticoagulation Therapy Point of Care guide with the second edition published in 2018. He is an active lecturer, both nationally and internationally, and has research interests involving anticoagulation, critical care, cardiovascular disease, and pharmacokinetics/pharmacodynamics.

Selected Publications

Trask A, Gosselin RC, Diaz J, Dager WE. Warfarin initiation and monitoring with clotting factors II, VII and X levels.  The Annals of Pharmacotherapy 2004;38:251-6.

Chan A, Dager WE. Systemic anticoagulant prophylaxis for central catheter associated venous thrombosis in cancer patients. The Annals of Pharmacotherapy 2007;41:635-41.

Heintz BH, Matzke GR, Dager WE.  Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis. Pharmacotherapy 2009;29:562-77.

Nagle E, Tsu L, Dager WE. Bivalirudin for Anticoagulation during Hypothermic Cardiopulmonary Bypass and Recombinant Factor VIIa for Iatrogenic Coagulopathy. The Annals of Pharmacotherapy 2011;45:e47

Tsu L, Dager WE.  Bivalirudin dosing patterns for renal function including presence of hemodialysis in the management of heparin induced thrombocytopenia. The Annals of Pharmacotherapy 2011;45:1185-92

Heintz BH, Thompson III GR, Dager WE. Clinical Experience with Aminoglycosides in Dialysis-Dependent Patients: Risk Factors for Mortality and Reassessment of Current Dosing Practices. The Annals of Pharmacotherapy 2011;45:1338-45

Tsu LV, Dager WE. Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2012;32:20-6.

Tsu LV, Dienes JE, Dager WE. Vitamin K Dosing to Reverse Warfarin Based on INR, Route of Administration, and Home Warfarin Dose in the Acute/Critical Care Setting. Ann Pharmacother. 2012;46:1617-26.

Nagle EL, Dager WE, Duby JJ, Roberts AJ, Kenny LE, Murthy MS, Pretzlaff RK. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatr Crit Care Med. 2013;14:e182-8.

Tsu LV, Dager WE. Safety of new oral anticoagulants with dual antiplatelet therapy in patients with acute coronary syndromes. Ann Pharmacother. 2013 Apr;47:573-7.

Pon TK, Dager WE, Roberts AJ, White RH. Subcutaneous enoxaparin for therapeutic anticoagulation in hemodialysis patients. Thromb Res. 2014;133:1023-8.

Dager W, Tsu L, Pon T. Considerations for Systemic Anticoagulation in ESRD. Semin Dial. 2015;28:354-62.

Chen LD, Roberts AJ, Dager WE. Safety and efficacy of starting warfarin after two consecutive platelet count rises in heparin-induced thrombocytopenia. Thromb Res. 2016;144:229-33.

Dager WE, Lee JA. Filtering Out Use of DOACs in Hemodialysis. Ann Pharmacother. 2017;51:511-513.

Steele AP, Lee JA, Dager WE. Incomplete dabigatran reversal with idarucizumab. Clin Toxicol (Phila). 2018;56:216-218.

Walker EA, Dager WE. Bridging with Tirofiban during Oral Antiplatelet Interruption: A Single-Center Case Series Analysis Including Patients on Hemodialysis. Pharmacotherapy. 2017;37:888-892.

Walker EA, Roberts AJ, Louie EL, Dager WE. Bivalirudin Dosing Requirements in Adult Patients on Extracorporeal Life Support with or without Continuous Renal Replacement Therapy. ASAIO J. 2018 Published on line

Jeremiah J. Duby, PharmD, BCPS, BCCCP, FCCM

Current Title(s):

  • Senior Clinical Pharmacist
  • Assistant Clinical Professor, Touro University College of Pharmacy
  • Assistant Clinical Professor, UC San Francisco School of Pharmacy
  • Assistant Clinical Professor, UC Davis School of Medicine

At UC Davis Medical Center since: 2007

Program Director since: 2010

Education:

  • Pharm.D., Washington State University, 2003
  • PGY-1 Acute Care Residency, University of Arizona, 2004
  • PGY-2 Critical Care Pharmacy Residency, University of Arizona, 2005

Professional Biography

Dr. Jeremiah Duby is the Senior Critical Care Pharmacist and Specialty Critical Care Residency Program Director for UC Davis Medical Center. He serves as Assistant Clinical Professor for Touro University (TU) College of Pharmacy, UCSF School of Pharmacy, and UC Davis School of Medicine.  His principle practice is in clinical patient care with Trauma Surgery, Burn Surgery, Medical ICU, and Parenteral Nutrition services.  These activities serve as inspiration for his roles in policy and protocol development and research.  Additionally, he provides didactic lectures for TU and UC San Francisco students on acute care topics that include clinical pharmacokinetics, fluid/electrolyte abnormalities, acute pain, sepsis/septic shock, acid-base disorders, skin-soft tissue infections, pneumonia, and clinical toxicology.  Current research interests range from alcohol withdrawal syndrome to diabetic ketoacidosis to acute arrhythmias.

Dr. Duby graduated from Washington State University (2003) and then a completed pharmacy practice residency (PGY-1, 2004, William L. Fritz, MS, FASHP) and critical care residency (PGY-2, 2005, Brian L. Erstad, Pharm.D., FCCM) with an emphasis in infectious diseases and nutrition at the University of Arizona Medical Center (UAMC).  He first served as an infectious diseases pharmacist for Kaiser Permanente (2005 – 2007), helping pilot and establish a successful antimicrobial stewardship service with Stephen M. Parodi, M.D., which later became as model of patient care for the region.

Selected Publications

Nagle E, Dager WE, Duby JJ, Roberts A, Murthy M, Kenny L, Pretzlaff R. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatric Critical Care Medicine. (pending press).

Nagle E, Murthy M, Medina M, Floyd K, Love, D, Duby JJ. Nursing clinical discretion and decisions in the provision of pharmacotherapy in the intensive care unit. [abstract/poster]. 42nd Critical Care Congress. San Juan, Puerto Rico: Display and Professor Walk Rounds. January 20, 2012.

Bajorek S, Duby JJ, Heintz S, Heintz H, Cocanour CS. Risk factors, prevalence, course, and complications of atrial fibrillation in critically ill trauma patients. 42nd Critical Care Congress. San Juan, Puerto Rico: Display and Professor Walk Rounds. January 20, 2013.

Murthy M, Nagle E, Parker P, Duby JJ. Doseresponse effect of rescue intravenous dextrose for hypoglycemia in critically ill patients. 42nd Critical Care Congress. San Juan, Puerto Rico: Display and Oral Presentation. January 20, 2013.

Berry A, Cocanour CS, Duby JJ. Management of Alcohol Withdrawal Syndrome (AWS) that Complicates the Course of Critically Ill Patients. [abstract/poster]. 41st Critical Care Congress. Houston, TX: Display and Professor Walk Rounds. February 7, 2012.

Murthy M, Nagle E, Duby JJ, Roach D, Parker P. Dose Response to Rescue Intravenous Dextrose Administration following Hypoglycemic Events with an Insulin Infusion Protocol in Critically Ill Burn Patients. [abstract/poster]. 41st Critical Care Congress. Houston, TX: Display and Professor Walk Rounds. February 7, 2012.

Nagle E, Pretzlaff R, Duby JJ, Roberts JA,Murthy M, Dager WE. A Case Series Describing the Use of Bivalirudin in Pediatric Patients Maintained on Extracorporeal Life Support. [abstract/poster]. 41st Critical Care Congress. Houston, TX. February 4, 2012.

VonMuenster SJ, Cocanour CS, Duby JJ. Prevalence and Course of Atrial Fibrillation (AF) in Critically Ill Trauma Patients. [abstract/poster]. Annual Meeting. Western Surgical Association. Tucson, AZ: Podium Presentation, November 13, 2011.

Matzke GR, Duby JJ. Vancomycin. In: Murphy JE. Clinical Pharmacokinetics. 5th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2011.

Duby JJ, Heintz BH. Clostridium difficile Associated Diarrhea. In: Katz MD, Matthias KR, Chisholm-Burns MA. Pharmacotherapy Principles and Practice Study Guide: A Case-Based Care Plan Approach. New York, NY: McGraw-Hill; 2010: 327 - 329.

Duby JJ. Ketamine: Pharmacology, Controversy, and Role. Clinical Pharmacy and Pharmacology Section Newsletter. Society of Critical Care Medicine. July 2010; 10(2).

Kopp B, Mrsan M, Erstad BL, Duby JJ. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. American Journal of Health-System Pharmacy. 2007; 64: 2483 – 2487.

Duby JJ, Erstad BL, Abarca J, Camamo JM, Huckleberry Y, Bramblett SN. Impact of delayed initiation of erythropoietin in critically ill patients. Blood Disorders. 2007; 7:1.

Duby JJ, Rollins CJ. Survey of nurse administration of phenytoin through enteral feeding tubes concomitantly with enteral nutrition. Poster: ASHP 2007 Summer Meeting and Exhibition. San Francisco, CA. June 25, 2007.

Patanwala AE, Duby JJ, Waters D, Erstad BL. Opioid Conversion in Acute Care. Annals of Pharmacotherapy. 2007; 41(2): 255 – 266.

Christopher B. Adams, PharmD, BCCCP

Current Title(s):

  • Senior Clinical Pharmacist, Emergency Medicine
  • Assistant Clinical Professor, UC San Francisco School of Pharmacy
  • Assistant Clinical Professor, UC Davis School of Medicine

    At UC Davis Medical Center since: 2014

    Program Director since: 2018

    Education:

    • Bachelor of Science, Loyola University New Orleans, 2008
    • Doctor of Pharmacy, Oregon State University, 2012
    • PGY1 Pharmacy Residency, Oregon Health & Science University, 2013
    • PGY2 Emergency Medicine, University of Rochester Medical Center, 2014

    Professional Biography

    Dr. Christopher Adams is the Senior Pharmacist in Emergency Medicine and the Emergency Medicine Pharmacy Residency Program Director for the University of California Davis Medical Center. Dr. Adams graduated from Oregon State University and Oregon Health and Science University (OHSU) in 2012 and then a completed a PGY1 Pharmacy Residency at OHSU in 2013. He then sought further education and experience in emergency medicine and completed the PGY2 Emergency Medicine Pharmacy Residency in 2014 at the University of Rochester Medical Center. Following residency he accepted a position with UC Davis Health, focusing on Emergency Medicine. Dr. Adams serves as an Assistant Clinical Professor for the UC San Francisco School of Pharmacy and precepts pharmacy students and residents in Emergency Medicine. Dr. Adams also serves as an Assistant Clinical Professor for the UC Davis School of Medicine where he teaches a Wilderness Medicine elective to medical, physician assistant and nurse practitioner students. In addition, he is a Ski Patroller in the Lake Tahoe region and is certified in Outdoor Emergency Care (OEC), Emergency Neurological Life Support (ENLS), Pediatric Advanced Life Support (PALS) and is an instructor for Advanced Cardiovascular Life Support (ACLS). Finally, Dr. Adams is a Board Certified Critical Care Pharmacist (BCCCP).

    Dr. Adams strives to play an instrumental role in the development of Emergency Medicine Pharmacy Services at UC Davis Health and beyond. He serves as a peer reviewer for the Annals of Emergency Medicine and Academic Emergency Medicine. He volunteers his time as part of the American Society of Health-System Pharmacists (ASHP) Section Advisory Group on Emergency Care and as part of the Acute Medical Team at the California International Marathon.

    Research is a driving force within UC Davis Health Emergency Department. Dr. Adams works closely with Emergency Medicine Faculty to ensure research and care initiative are successful. His research interests include Emergency Medicine Pharmacy educational opportunities locally and nationally, tranexamic acid and substance abuse disorders.

    Dr. Adams has been involved with the UC Davis Health PGY2 Emergency Medicine Pharmacy Residency Program since its inception in 2014. In 2018, Dr. Adams was appointed to Residency Program Director and hopes to expand the residency to diversify clinical services and maximize the cultivation of outstanding pharmacists with a prospective career in Emergency Medicine Pharmacy.

    Selected Publications

    Catlin JR, Adams CB, Louie DJ, Wilson MD, Louie EN. Aggressive versus conservative initial diuretic dosing in the emergency department for acute decompensated heart failure. Ann Pharmacother. 2018;52(1):26-31.

    Adams CB, Vollman KE, Leventhal EL, Acquisto NM. Emergent pediatric anticoagulation reversal using a 4-factor prothrombin complex concentrate. Am J Emerg Med. 2016;34(6):1182.e1-2.

    Adams CB, Acquisto NM, Rotoli JM, Lostracco T, Shamaskin AR, Pasternack JS. Superior mesenteric artery thrombosis after abrupt discontinuation of rivaroxaban. Am J Emerg Med. 2016;34(4):764.e5-7.

    Vollman KE, Adams CB, Shah, MN, Acquisto NM. Survey of emergency medicine pharmacy education opportunities for students and residents. Hosp Pharm. 2015;50(8)690-99. Adams CB, Schult R, Acquisto NM, Wiegand TJ. 2014 Annual Meeting of the North American Congress of Clinical Toxicology: Bupropion exposures seizures and severe toxicity. Clin Toxicol (Phila). 2014;52(7)769-70.

    Buxell S, Adams CB. Pharmacy Pulse. Department of Pharmacy, Oregon Health & Science University. Oct 2012; Apr 2013

    Seaton S, Lyons K, Flannery A, Adams CB, Birk R, Lettsome R, Mottice B, Pon T, Siv M. Student Commentary: Purpose and Impact of Introductory Pharmacy Practice Experiences. Pharmacotherapy. June 2011 [accepted]

    Seaton S, Lyons K, Flannery A, Adams CB, Birk R, Lettsome R, Mottice B, Pon T, Siv M. National Student Newsletter: StuNews. American College of Clinical Pharmacy website. www.accp.com. Jan 2011; Apr 2011; Aug 2011; Dec 2011; Mar 2012; June 2012; Aug 2012

    Monica Donnelley, PharmD, BCIDP, BCPS AQ-ID, AAHIVP

    Current Title(s):

    • Senior Pharmacist, UCD Health, Infectious Diseases
    • PGY2 Infectious Diseases Residency Program Director
    • Assistant Clinical Professor:
      • Touro University, College of Pharmacy
      • UC Davis, School of Medicine
      • UC San Francisco, School of Pharmacy

    Education:

    PharmD., Touro University, Mare Island, 2010

    Post-graduate Training:

    PGY1 Pharmacy Practice Residency, UC Davis Medical Center, 2010-2011

    PGY2 Infectious Diseases Residency, UC Davis Medical Center, 2011-2012

    Research Interests

    New agents: antimicrobials and antifungals, antimicrobial dosing in critically ill, improving antimicrobial stewardship services, Outpatient Parenteral Antimicrobial Therapy (OPAT), and reducing C. difficile infections.

    Practice Philosophy

    I am an antimicrobial advisor. My goal is to create customized therapy plans for each patient based on a multitude of factors. Understand that each patient is different from the neonate to someone’s great-grandmother, the gymnast from the linebacker. The world of ID is fascinating and not only is the patient and the drug involved critical to consider in therapy decisions, but we must also consider the “bug” where did it come from, is it resistant, and can we reach it with our therapy.

    Rotations Precepted

    Infectious Diseases Consult (PGY1 and PGY2)

    Antimicrobial Stewardship (PGY1 and PGY2)

    Infectious Diseases Pediatric Consult (PGY2)

    Additional PGY2 ID rotations precepted, please see PGY2 in Infectious Diseases Link

    Professional Biography

    Dr. Monica Donnelley is board certified in infectious diseases and pharmacotherapy. She is also certified as an American Association of HIV Pharmacist. She is a Senior Pharmacist at UC Davis Health. Dr. Donnelley began her pharmacy career at UC Davis Health in 2010 after graduating from pharmacy school. At Touro University College of Pharmacy, she was the recipient of the Mylan Institute Pharmacy Excellency Award and won the California Society of Health System Pharmacist Clinical Skills Competition. She went on to complete a PGY1 Pharmacy Practice Residency and PGY2 Infectious Diseases Residency at UC Davis Health.

    Following completion of her ID PGY2 she accepted a position with UC Davis Health, focusing on infectious diseases and medication safety. Concurrently she also began teaching at Touro University (TU), College of Pharmacy in the Clinical Sciences track and obtained a volunteer faculty position as an assistant professor with the University of San Francisco, College of Pharmacy and the University of California, Davis School of Medicine. In 2013 she was awarded Professor of the Year in Clinical Sciences at TU.

    After practicing for five years at UC Davis Health, Dr. Donnelley was promoted to Senior Pharmacist and in 2016 she assumed directorship of the long standing PGY2 infectious diseases residency program upon the retirement of her PGY2 residency director Cinda Christensen. For the 2016–2017 year, she was awarded Residency Preceptor of the Year and in 2017–2018 she received the Research Preceptor of the Year award. Monica loves to work with learners. She contributes to the care of patients through actively rounding with infectious diseases, research, publications, committee work, and guideline development.

    Andrea Iannucci, Pharm.D., BCOP

    Current Title(s):

    • Assistant Chief, Oncology and Investigational Drug Services
    • Oncology Pharmacy Specialist, UC Davis Medical Center Pharmacy Services
    • Health Sciences Clinical Professor, UC San Francisco School of Pharmacy and UC Davis School of Medicine

    At UC Davis Medical Center since: 2002

    Program Director since: 2004

    Education:

    • Pharm.D., UC San Francisco School of Pharmacy
    • PGY-1 Pharmacy Residency, UC San Francisco
    • PGY-2 Oncology Residency, MD Anderson Cancer Center

    Professional Biography

    Dr. Andrea Iannucci has practiced in oncology pharmacy for 25 years. In the past, she has also served as a full-time faculty member at the University of Colorado School of Pharmacy and as the Director of Clinical Services for the Rocky Mountain Cancer Centers.  Andrea joined the UC Davis Pharmacy team in 2002 as a Senior Oncology Pharmacist.  She started the PGY2 Oncology Residency Program in 2004 and has graduated nearly 20 oncology pharmacists from the program.  Andrea has served as an IRB member with the UC Davis Medical Center IRB. She currently serves as a member of the UC Davis Cancer Center Scientific Review Committee. Andrea is the co-chair of the Oncology Sub-Committee of the UC Davis Pharmacy and Therapeutics Committee and she oversees the operations of oncology pharmacy and investigational services at UC Davis.   Andrea has also been involved in the Board of Pharmaceutical Specialties (BPS) Oncology Specialty Council and most recently served on the BPS Board of Directors, where she has served as the BPS chair. 

    Selected Publications

    Iannucci A, Reed Jeanne, Bell T.  “Chapter 21: Cancer and Chemotherapy” in Pharmacology Essentials for Technicians, 2011; Paradigm Publishing, Inc. (St. Paul, MN).

    Rao, KV, Iannucci AA, Jabbour E.  Current and Future Clinical Strategies in the Management of Chronic Myeloid Leukemia.  Pharmacotherapy 2010;30(9 Pt 2):77S–101S.

    Superfin D, Iannucci AA, Davies A. Commentary: Oncologic Drugs in Organ dysfunction: A Summary. The Oncologist, 2007;12;1070-1083.

    Iannucci A and Chan, A.  “Management and Treatment of Hematologic Toxicities” in Unit 3, Supportive Care in Mosby’s Oncology Drug Reference, 2007; Mosby Elsevier (St. Louis, MO).

    Stull DM, Iannucci A, Bertin R.  Board-Certified Oncology Pharmacists: Partners in the Multidisciplinary Care of Cancer Patients. Community Oncology, 2006;3(5):284-286.

    Balmer CM, Valley AW, Iannucci A.  Cancer Treatment and Chemotherapy in Pharmacotherapy: A Pathophysiologic Approach, 6th Edition.  DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors, 2005, McGraw-Hill Companies, Inc.

    Chan A, Iannucci A, Dager WE. Systemic Anticoagulant Prophylaxis for Central Catheter-associated Venous Thrombosis in Cancer Patients.  Annals of Pharmacotherapy 2007, 41:635-641.

    Gibbs P, Iannucci A, Allen J, O'Driscoll M, McDowell K, Williams P, Rosse P, Murphy J, Gonzalez R.  A Phase II Study of Biochemotherapy for the Treatment of Metastatic Malignant Melanoma.  Melanoma Research, 2000; 10: 171-179.

    Charity Hale, Pharm.D.

    Charity Hale, Pharm.D.

    Current Title(s):

    • Pain Management and Palliative Care Clinical Staff Pharmacist
    • PGY2 Pain Management and Palliative Care Residency Program Director
    • Assistant Clinical Professor at the University of California, San Francisco, School of Pharmacy

    Education:

    • Tennessee Technological University, Bachelor’s Degree in Molecular Genetics (2009)
    • Union University School of Pharmacy, Doctorate of Pharmacy (2013)

    Post-graduate Training:

    • North Mississippi Medical Center, PGY1 Acute Care Residency (2014)
    • University of California, Davis Medical Center, PGY2 Pain Management and Palliative Care (2015)

    Research Interests

    Development and validation of an EMR screening tool that stratifies patients into high, medium and low risk groups for opioid-induced respiratory depression and over sedation.

    Appropriate post-operative opioid use following total hip and knee arthroplasty.

    Opioid conversion calculator.

    The effectiveness of low dose oral ketamine for cancer related pain.

    Practice Philosophy

    Aspiring to provide timely, compassionate and effective patient care that alleviates pain and suffering.

    Rotations Precepted

    Inpatient Pharmacy Pain Management

    Outpatient Pain Management Clinic

    Professional Biography

    Dr. Charity Hale is a Pain Management and Palliative Care Pharmacist at UC Davis Health. Hale began her pharmacy career at North Mississippi Medical Center in 2013 after graduating from pharmacy school. At Union University School of Pharmacy, she participated in the ASHP Clinical Skills Competition. She went on to complete a PGY1 Acute Care Residency at North Mississippi Center and a PGY2 in Pain Management and Palliative Care at the University of California, Davis Medical Center.

    Following completion of her PGY2, she accepted a position at UCDH as a Pain Management and Palliative Care Clinical pharmacist. Concurrently, Dr. Hale began teaching an Interdisciplinary Pain Management and Palliative Care Course at the University of California, San Francisco School of Pharmacy and at the University of California, Davis School of Medicine.

    After practicing for five years at UCDH, Dr. Hale received the Pain Management Certificate through ASHP and was promoted as the PGY2 Pain Management and Palliative Care Residency Program Director. She serves as a preceptor for students, residents, and fellows through the Department of Pharmacy, Department of Internal Medicine and Department of Anesthesiology. 

    Dr. Hale works full time in direct patient care and serves a wide range of patient populations.  Her focuses include academia, mentoring learners, innovations, staff competencies, quality improvement, peer journal reviews, publications, committee involvement and research.

    Selected Publications

    Hale,C.,et al. Nonsteroidal Anti-Inflammatory Drugs. De Mesa, C. Primary Care Pain Management. Wolters Kluwer. 2020.

    Holtsman, M. Hale,C. Opioids used for Mild to Moderate Pain. Benzon HT, Raja SN, Liu SS, Fishman SM, Cohen SP eds. Essentials of Pain Medicine and Regional Anesthesia. Philadelphia: Elsevier Churchill Livingstone. 2018.

    Brent Hall, Pharm.D., BCPPS

    Current Title(s):

    • Senior Pharmacist, Pediatrics
    • Assistant Clinical Professor, UCSF School of Pharmacy

    At UC Davis Medical Center since: 2014

    Program Director since: 2015

    Education:

    • PGY 1 Northwestern Memorial Hospital, Chicago, IL, July 1999-June 2000
    • Pharm.D., Purdue University School of Pharmacy, 1999
    • BS Biology/Physiology, Purdue University School of Science, 1998

    Professional Biography

    Brent Hall is currently a Senior Pharmacist in Pediatrics at the UC Davis Medical Center.  After completion of his residency, Brent accepted a position at University Medical Center in Tucson, Arizona.  This institution served as the teaching hospital for the University of Arizona Schools of Pharmacy, Medicine, Nursing and Public Health.  Brent first served as a staff pharmacist in pediatrics before advancing to the position of  Clinical Coordinator for Pediatric Pharmacy.  Over the 14 years that he spent in Arizona he was able to grow his service from 1 FTE to 4 FTEs with an expanding precepting program for University of Arizona pharmacy students as well as helping to lay the groundwork for the development of a PGY 2 Pediatric Pharmacy Residency Program.  Brent was also very active in the Schools of Pharmacy, Medicine and Nursing providing didactic lectures, precepting and course coordination.  In 2014, Brent moved his practice to Sacramento, California to help with the establishment of the PGY 2 Pediatric Pharmacy Residency Program and expansion of clinical services.  Brent is actively involved with programs at UC Davis Children’s Hospital which include Chairman of the Too Keep Open Protocol Development Team, Co-Chair of the Department of Pharmacy Committee on Education, Pediatric Heart Center Group for protocol development, UC Davis Pediatric Pain Team, Pediatric Medication Error Committee and PICU Committee Representative.  Nationally he is actively involved in ACCP, PPAG and has worked on the A-F Bundle Project with SCCM as well as Opioid Stewardship programs with Delphi.   Brent’s areas of interest include critical care medicine, sedation/delirium management and pain control.

    Selected Publications

    “QTc prolongation in hospitalized pediatric patients receiving methadone” Schwinghammer, A; Wilson, M; Hall, B.  Ped Crit Care Med – accepted, publication date pending

    “Dexmedetomidine Use in Critically Ill Children with Acute Respiratory Failure” Grant, M; Schneider, J; Asaro, L; Dodson, B; Hall, B; Simone, S; Cowl, A; Munkwitz, M; Wypij, D; Curely, M. Pediatric Crit Care Med, 2016 Dec; 17(12):1131-41.

    “Neonatal Extravasation: An Overview and Algorithm for Evidence-Based Treatment” Beall, V; Hall, B; Mulholland, J.; Gephart, S. Newborn and Infant Nursing Reviews Journal, Vol 13, Number 4, December 2013, pp189-95.

    Current Research Projects

    “Randomized, Placebo Controlled, Trial to Evaluate the Use of Gabapentin in Pediatric Cardiothoracic Surgery Patients to Reduce Opioid Requirements Post Operatively”  Hall, B, Raff, G – Grant application under review

    “A Non Inferiority Trial Comparing TKO Rates on Need for Line Replacement in Pediatric Patients” Bhavsar, V; McLearan, H; Mooney, P; Signoff, J; Hall, B – Data Collection is ongoing, expected data analysis to start 2020

    “Assessment of pain/sedation protocol for mechanically ventilated patient’s in UC Davis Childrens’ Medical Center PICU”, Data collection ongoing, expected data analysis to start 2020

    “A Randomized, Placebo Controlled, Double Dummy Trial to Evaluate a Single Preoperative Oral Acetaminophen Dose vs IV on Postoperative Opioid Use in Patient’s Undergoing Tonsillectomy”, Lammers, C; Schwinghammer, A; Hall, B; Applegate, R. – Enrollment ongoing with expected data analysis to start January 2019

    Patricia Poole, PharmD, BCPS AQ-ID, AAHIVP, BCACP

    Current Title(s):

    • Manager, Educational Enterprise
    • Associate Clinical Professor, UC San Francisco School of Pharmacy
    • Associate Clinical Professor, UC Davis School of Medicine
    • Residency Program Director, PGY2 Ambulatory Care

    At UC Davis Medical Center since: 1989

    Program Director since: 2019

    Program Director for PGY-1 Ambulatory Care/HIV: 2008-2017

    Education:

    • Doctor of Pharmacy, University of the Pacific, 1988
    • PGY1 Pharmacy Residency, UC Davis Medical Center, 1989

    Professional Biography

    Dr. Poole became a Pharmacy Manager, overseeing the Education Enterprise at UC Davis Health (UCDH) in 2019.  In this capacity, she oversees all 12 of unique PGY1 and PGY2 Pharmacy Residency Programs, student programs, and staff development and education. Her prior role, was as a Pharmacist Specialist at UC Davis Health, Department of Pharmacy, Ambulatory Care Division and she continues to influence the advancement of the Ambulatory Clinical programs at UCDH.  Her clinical practice in ambulatory practice has focused on the specialized pharmacotherapy of people living with HIV/AIDS, Viral Hepatitis, and Cystic Fibrosis. Dr. Poole is a Board-Certified Pharmacotherapy Specialist, with Added Qualifications in Infectious Diseases through the American College of Clinical Pharmacists as well as a Certified HIV Pharmacist through the American Academy of HIV Medicine. She holds academic appointments as Health Sciences Associate Clinical Professor, Department of Internal Medicine, Division of Infectious Diseases, UC Davis as well as Associate Clinical Professor, School of Pharmacy, Department of Clinical Pharmacy, UC San Francisco. As manager of the UC Davis Pharmacy Residency training programs, she collaborates with other training sites across the University of California Health System to conduct clinical research in pharmacotherapy, serves on the California Society of Health system Pharmacists Opioid Task Force, and also serves as a guest surveyor for ASHP residency accreditation.

    Research is a driving force within UCDH Department of Pharmacy and Dr. Poole co-chairs the Pharmacy Research Oversight Committee. Her research interests include Specialty Pharmacy, Population Health, Underserved Populations, and Substance Use Disorders.

    Dr. Poole earned her Doctor of Pharmacy, Summa Cum Laude at the University of the Pacific School of Pharmacy and completed a Post-Graduate Pharmacy Residency at UC Davis Health.

    POSTER PRESENTATIONS-National Meetings

    Shannan Takhar, Patricia Poole. THE IMPACT OF A MULTIDISCIPLINARY CONTROLLED SUBSTANCE COMMITTEE ON REDUCING OPIOID PRESCRIBING. ACCP Annual Meeting (October) 2019, New York City, NY.

    David M. Asmuth, Annie Y. Chen, Netanya S. Utay, Natalie Torok, Patricia L. Poole, Joy Vongspanich, Kathleen R. Haight, Anoma D. Sumasunderam, Enkhmaa Byambaa, Xiao-Dong Li, Stuart T. Cohen, Lars Berglund, Mark Holodniy, Thomas I. Michalak. IMPACT OF OCCULT HCV INFECTION (OCI) ON SYSTEMIC IMMUNE ACTIVATION AFTER DAA THERAPY (ID 1053). Conference on Retroviruses and Opportunistic Infections (CROI), (March)2018, Boston, Massachusetts.
    Cindy Banh, Rebecca Hluhanich, Kathleen Haight, Patricia Poole. : Abstract 58395: Effects of Acid-Reducing Agents on SVR12 Rates for hepatitis C Patients Treated with Ledipasvir/Sofosbuvir.  Infectious Disease Society of America ID Week 2016, (Oct) 2016, New Orleans, LA.

    Rebecca Hluhanich, Joy Vongspanich, Machelle Wilson, Patricia L. Poole.  Management of Hypertensive HIV-positive Patients in a Patient-Centered Medical Home.  ACCP Annual Meeting poster presentation #311 (Oct) 2014, Austin, TX.

    Kathleen Haight, Patricia L. Poole, Chin-Shang Li. Addressing Virologic Failure in HIV-Positive Patients Through the Patient Centered Medical Home Care Model. Infectious Disease Society of America ID Week 2013, (Oct) 2013, San Francisco, CA.

    Jennifer Nguyen, Patricia Poole, Sharon Myers, Kathy Tong, Erin Griffin, Brigit Levich. Impact of a Collaborative Heart Failure Pharmacist and Nurse Pilot Project in the UC Davis Health System Primary Care Network. Heart Failure Society of America, (Sep) 2013, Orlando, FL

    Rory Okasaki Gutierrez, Patricia Poole, and David Asmuth. Prevalence of Subclinical Iatrogenic Cushing’s Syndrome in Patient’s Being Co-Administered Ritonavir and Corticosteroids via Inhaled, Intranasal, and/or Topical Route. XIX International AIDS Conference (July) 2012, Washington DC

    Lawal A, Poole P. Retrospective Evaluation of Methadone and Cardiac Conductions Side Effects in HIV positive patients.  ASHP Midyear Clinical Meeting (Dec) 2009, UHC Annual Meeting

    Quezada V; Siddiqui J; Poole P.  Polypharmacy in the management of Human Immunodeficiency Virus (HIV) patients. ASHP Midyear Clinical Meeting (Dec) 2008, UHC Annual Meeting

    Romac DR, Poole PL: Phasing out midazolam at a University Teaching Hospital.  32nd ASHP Midyear Clinical Meeting 32:P-242D (Dec) 1997.

    Poole PL, Romac DR: Erythropoietin in the Treatment of Anemia Related to Myelodysplasia. 31st ASHP Midyear Clinical Meeting, December, 1996.

    Poole PL, Romac DR, King JH: Cost-Effective Management of Sedation with Intravenous Benzodiazepines and Propofol Continuous Infusions.  30th ASHP Midyear Clinical Meeting, December, 1995.

    PUBLICATIONS

    Poole, P: Pantoprazole, Formulary Review. Am J Health-Syst Pharm Jun 1, 2001;58:999-1008.

    Poole, PL: Pantoprazole. UHC Drug Monograph 2000: Volume 8.

    Romac, DR, Poole PL: The role of the pharmacist in anticoagulant therapy: Patient education and counseling. Health Notes 1999: 1:3.

    Romac DR, Poole PL, Owings JT, et al:  Development of Guidelines for Biotechnology Drug Use as a Tool in Formulary Management: Antithrombin III.  Hospital Formulary, 1995;30:9.

    Poole PL: Medication Formulary Management: Future Trends. Drug Perspectives 1995;17:1.

    Poole PL: Preferential Use of Diazepam (Valium) as the Intravenous Benzodiazepine of Choice.  Drug Perspectives 1995;17:1.

    Poole PL, Branch JM: Use of intravenous benzodiazepines and propofol at UC Davis Medical Center. Drug Perspectives 1993:16:4.

    Poole PL:  Pancreatic enzyme supplements.  Drug Perspectives 1989;12:7.

    Poole PL:  How pharmacy associations protect members' livelihood, future - Commentary.  California Pharmacist 1988;9:20.

    Ashley Trask, Pharm.D.

    Current Title(s):

    • Pharmacy Supervisor, Medication Policy & Safety

    At UC Davis Health since: 2002

    Program Director since: 2016

    Education:

    • PGY-1 Pharmacy Residency, University of California, Davis Medical Center, 2002
    • Pharm.D., University of Florida, 2002

    Professional Biography

    Dr Ashley Trask is the Medication Policy & Safety Pharmacist Supervisor, overseeing pharmacy teams who support the Pharmacy & Therapeutics committee, medication safety and medication security efforts at University of California Davis Health.  She received her Doctor of Pharmacy from the University of Florida, College of Pharmacy in 2002, and completed her Pharmacy Practice Residency at UC Davis Medical Center in 2003. Dr Trask took an interest in pain management and began her pharmacy career in 2003 at UC Davis as a Pain Management Pharmacist, providing consultations for inpatients. After many years of serving patients at the bedside, Dr Trask transitioned into a more administrative role, where she began engaging in quality improvement activities associated with medication-related events, and assisting the health system in complying with new state laws directed at medication safety. Dr Trask has a passion for equipping clinicians with the skills to improve the safe use of medications in their practice settings. Dr Trask is a member of several interdisciplinary task forces and committees focused on improving the quality and safety of healthcare for patients at UC Davis Health.  She was promoted to her current role as a pharmacy supervisor in 2015 and serves as the residency director for the Post Graduate Year 2 Pharmacy Practice Resident in Medication Use Safety, as well as the primary preceptor for pharmacy students and pharmacy practice residents on the Medication Safety and Hospital Operations rotations.  Dr Trask currently resides in Sacramento with her husband and three sons.

    Featured Presentations

    Drug Shortages and Surplus Risk- Addressing Drug Shortages with a Patient Safety Perspective, CSHP Seminar 18, October 5, 2018

    RADEO Project Interdisciplinary Group Meeting, UC Davis ANCC Magnet Site Visit, August 2018

    Reducing Opioid Adverse Drug Events, Vizient Webinar, Performance Improvement Collaboratives Series 2017—Program 1, October 25, 2017

    A Pilot Program at UC Davis Medical Center to Reduce Adverse Drug Events Related to Opioids, Greater Sacramento Care Coordination Learning and Action Network Conference, October 9, 2017

    Selected Publications

    Assessing the Effectiveness of a Clinical Decision Support Tool on Recognition and Documentation of Suspected Heparin-Induced Thrombocytopenia (HIT). [poster] UC Davis Quality Symposium; April 2015.

    Repurposed Data to Measure Physician Quality of Care– Can Prescribing Errors be Detected from Decision Support Systems Data? [abstract] EDM Forum Stakeholder Symposium; June 2013.

    Note to applicants: Please direct application materials (via PhORCAS) to the respective program director above.

    Please direct questions to: hs-rxresidency@ucdavis.edu